endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

R&D channel feed

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

5 days ago

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

6 days ago

Q&A: Why for­mer Sen. Kyrsten Sine­ma is back­ing a psy­che­del­ic med­i­cine with po­ten­tial­ly more up­side, but more risk

6 days ago
People

Pfiz­er's Braftovi com­bo dou­bles sur­vival time for some col­orec­tal can­cer pa­tients

6 days ago
Pharma

Sanofi, Re­gen­eron re­port un­der­whelm­ing COPD da­ta for IL-33 an­ti­body, shares drop

6 days ago

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

6 days ago

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

Last week

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

Last week
Pharma

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

Last week

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Last week

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Last week
FDA+

GSK, Spero re­port Phase 3 win for UTI an­tibi­ot­ic; Sper­o's stock soars

Last week

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

Last week

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

Last week

Bound­less Bio changes plans for can­cer drug af­ter tox­i­c­i­ty is­sues

Last week
People

Gil­gamesh’s short-act­ing psy­che­del­ic drug shows rapid ef­fect in Phase 2 de­pres­sion study

Last week

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

Last week
People

Ku­ra spells out piv­otal AML tri­al win as it gears up to com­pete with Syn­dax

Last week

Gilead notch­es an­oth­er Phase 3 win for Trodelvy in triple-neg­a­tive breast can­cer

Last week
Pharma

Volas­tra un­veils first hu­man da­ta of its sol­id tu­mor drug tar­get

Last week

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

2 weeks ago

Roche con­firms over­all sur­vival ben­e­fit for PI3K in­hibitor in breast can­cer

2 weeks ago
Pharma

Jazz out­lines full sur­vival da­ta for lung can­cer drug Zepzel­ca

2 weeks ago
Pharma

BioN­Tech in­vests £1B in grow­ing UK foot­print un­der ex­pand­ed pact with gov­ern­ment

3 weeks ago
Deals
First page Previous page 12345 Next page Last page
A service from the Financial Times